Skip to main content

Table 2 Outcomes for women undergoing assisted reproductive treatment

From: Vitamin D and assisted reproductive treatment outcome: a prospective cohort study

  Deficienta
< 50 nmol/L
n/N
% (95% CI)
Insufficienta
(50-75 nmol/L)
n/N
% (95% CI)
Repletea
(> 75 nmol/L)
n/N
% (95% CI)
p-value
Live birth Crude rates 57/246
23.2 (18.0–28.4)
38/141
27.0 (19.6–34.3)
29/77
37.7 (26.9–48.5)
0.04
Adjusted ratesb 24.3 (18.7–29.9) 27.1 (19.9–34.2) 34.4 (23.9–44.9) 0.25
Positive pregnancy test Crude rates 80/246
32.5 (26.7–38.4)
55/141
39.0 (30.9–47.1)
37/77
48.1 (36.9–59.2)
0.04
Adjusted ratesb 34.1 (27.9–40.4) 36.7 (28.7–44.8) 43.8 (32.5–55.2) 0.35
Clinical pregnancy Crude rates 64/246
26.0 (20.6–31.4)
45/141
31.9 (24.2–39.6)
32/77
41.6 (30.5–52.6)
0.03
Adjusted ratesb 27.1 (21.2–33.0) 32.0 (24.3–39.7) 38.7 (27.7–49.7) 0.19
Biochemical pregnancy loss Crude rates 16/80
20.0 (11.2–28.8)
10/55
18.2 (8.0–28.4)
5/37
13.5 (2.5–24.5)
0.70
Adjusted ratesb 21.6 (11.6–31.5) 16.1 (5.7–26-5) 14.2 (2.2–26.1) 0.64
Clinical pregnancy loss Crude rates 7/64
10.9 (3.3–18.6)
7/45
15.6 (5.0–26.1)
3/32
9.4 (0.1–19.5)
0.67
Adjusted ratesb 12.2 (4.2–20.2) 22.2 (7.7–36.7) 16.3 (1.8–30.9) 0.55
  1. aAs defined by Endocrine Society
  2. bAdusted for age, body mass index, ethnicity, smoking status, cause of infertility, duration of infertility, baseline pituitary follicular stimulating hormone assay, treatment protocol, and type of treatment